SecBot SecBot
Biotech Drug Report Generated Nov 8, 2026

Phesgo

HALO·HALOZYME THERAPEUTICS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since June 2020 (FDA) and December 2020 (EU).
Why 4/10
Phesgo is already FDA-approved (June 2020) and commercially established with no pending regulatory decision or pivotal readout; the next catalyst is simply ongoing commercial performance reported quarterly, which is not a hard binary event, so the impactScore is capped at 4.
Actionable Insight NEUTRAL

Phesgo is a mature, approved product with no pending FDA decision. Watch Halozyme's quarterly royalty revenue reports for Phesgo's commercial trajectory, and monitor Roche's quarterly sales disclosures for Phesgo growth trends. Any label expansion or new indication for Phesgo would be a positive catalyst for Halozyme's royalty stream.

Price Chart

Loading chart...

Executive Summary

Phesgo is a fixed-dose subcutaneous injection combining Roche's breast cancer drugs Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, using Halozyme's ENHANZE drug-delivery technology. FDA-approved in June 2020 and EU-approved in December 2020 for HER2-positive breast cancer, it converts hours-long IV infusions into minutes-long injections. The drug is developed and commercialized by Roche/Genentech (RHHBY), not Halozyme. Halozyme (HALO, Nasdaq) earns royalties on Phesgo sales through its ENHANZE licensing agreement with Roche. Phesgo contributed to Halozyme's record Q3 2026 royalty revenue of $341 million (up 44% YoY). With no pending regulatory catalysts, Phesgo is a mature commercial product that provides steady, growing royalty income for Halozyme but does not represent a binary event for the stock.

How It Works

Phesgo is a fixed-dose combination of two cancer drugs (pertuzumab and trastuzumab) plus hyaluronidase, given as a quick injection under the skin. Pertuzumab and trastuzumab are antibodies that bind to the HER2 protein on certain breast cancer cells and signal the immune system to attack them. The hyaluronidase enzyme (Halozyme's ENHANZE technology) temporarily breaks down a gel-like substance under the skin, allowing the large volume of medicine to be absorbed rapidly. This replaces the traditional method of giving these two drugs separately through an IV infusion that takes hours.

Trial Status

Phesgo received initial FDA approval on June 29, 2020, for HER2-positive breast cancer (early and metastatic). It received a supplemental FDA approval on November 22, 2024, and EU approval in December 2020. The drug is fully commercialized by Roche/Genentech.

The Two-Sided Case

▲ Bull Case5
Phesgo is a blockbuster product that generated strong sales growth for Roche, contributing to Halozyme's record Q3 2026 royalty revenue of $341 million (up 44% YoY).
Phesgo offers faster subcutaneous administration (minutes vs hours for IV), and 85% of patients preferred it over IV in trials, driving adoption.
Halozyme raised its full-year 2026 guidance after Q3, reflecting confidence in continued royalty growth from Phesgo and other ENHANZE-partnered products.
The ENHANZE platform has deep partnership moats; Roche's Phesgo and Herceptin Hylecta both use it, creating a recurring royalty stream.
Halozyme projects zero to minimal impact to royalty revenue through at least 2035 from Medicare drug price negotiation, providing long-term visibility.
▼ Bear Case5
Phesgo is a Roche drug, not a Halozyme drug; Halozyme only earns a royalty on sales, limiting its upside exposure.
HALO stock dropped ~15.7% on Nov 6, 2026 despite a Q3 earnings beat and raised guidance, reflecting a Leerink downgrade and concerns that growth is already priced in.
CEO Helen Torley sold shares worth ~$1.3M in October 2026 under a 10b5-1 plan, and other insiders also sold, signaling limited near-term upside conviction.
Biosimilar competition to Herceptin and Perjeta could eventually pressure Phesgo sales and Halozyme's royalties.
Phesgo faces competition from other HER2-targeted therapies and subcutaneous formulations.

Upcoming Catalysts

  • Halozyme quarterly earnings reports (next: Q4 2026, expected Feb 2027) showing royalty revenue trends from Phesgo and other ENHANZE-partnered products.
  • Any potential label expansion or new indication for Phesgo by Roche.
  • Roche quarterly sales disclosures for Phesgo growth trajectory.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

HALOZYME THERAPEUTICS, INC. 8-K HALO ·Originating report

Sources · 7

Hover a chip for the title
1 nasdaq.com2 reuters.com3 securities.io4 msn.com5 247wallst.com6 fiercepharma.com7 investors.com